ConnectiveRx

ConnectiveRx, based in the US, specializes in enhancing patient access to medications through comprehensive support programs and affordable solutions tailored for healthcare providers and pharmaceutical manufacturers. Founded in 2009, ConnectiveRx, also known as PSKW, LLC, operates from its headquarters in the United States. The company focuses on providing solutions that streamline patient access to necessary therapies. In March 2020, ConnectiveRx underwent a recapitalization, with Genstar Capital Partners leading the investment, now holding a majority stake alongside minority stakeholders Harvest Partners and Blackstone Group.

The total amount raised through this recapitalization was USD 300. 00 mn. ConnectiveRx offers a comprehensive suite of products and services designed to streamline access to medications for patients, healthcare providers, and pharmaceutical manufacturers. Their core offerings include end-to-end patient support programs, affordability solutions, and adherence messaging tailored to the specialty drug ecosystem.

These services are aimed at overcoming the challenges associated with obtaining necessary therapies, ensuring that patients can initiate and maintain their treatment regimens effectively. The company primarily serves a diverse clientele that includes pharmaceutical manufacturers, healthcare providers, and patients seeking affordable medication options. ConnectiveRx generates revenue through partnerships and B2B transactions with pharmaceutical manufacturers and healthcare providers. Their revenue model is based on service agreements and support contracts, where clients pay for access to ConnectiveRx's integrated platform designed to facilitate medication access.

Clients subscribe to various service tiers reflecting the scope and scale of the services utilized, which enhance point-of-care awareness and improve patient adherence. Partnerships with healthcare providers enable the company to activate a wide network of clinicians, ensuring that both specialty drug manufacturers and patients benefit from enhanced access and support services. Looking ahead, ConnectiveRx aims to leverage the USD 300. 00 mn raised during its recapitalization to support strategic initiatives, including the development of new products and expansion into new geographic markets.

The company is focused on enhancing its service offerings and is exploring specific new markets for expansion. The recapitalization will provide the necessary resources for these growth strategies, allowing ConnectiveRx to better serve the evolving needs of patients and healthcare providers in the specialty drug ecosystem.